SLC5A2 and type 2 diabetes mellitus: DAPA, a selective SGLT2 inhibitor, originally approved for the treatment of type 2 diabetes mellitus, has shown favorable effects on cardiovascular outcomes, especially in patients with chronic heart failure and reduced ejection fraction [14].